BC Week In Review | Mar 24, 2014
Company News

Meda, Mission Pharmacal sales and marketing update

Mission Pharmacal received rights to promote Meda's Elestrin estradiol gel in the U.S. The bioidentical estradiol transdermal gel is approved in the U.S. to treat moderate to severe hot flashes and night sweats associated with...
BC Week In Review | Oct 22, 2012
Company News

Jazz Pharmaceuticals, Meda sales and marketing update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland   Meda AB (SSE:MEDAA), Solna, Sweden   Business: Genitourinary   Meda acquired Jazz's women's health business for $95 million in cash. The business includes six products: Elestrin estradiol gel...
BC Week In Review | Dec 21, 2009
Company News

Azur Pharma, BioSante sales and marketing update

Azur will pay $1 million to BioSante in exchange for reducing the royalties that Azur owes BioSante on U.S. sales of Elestrin estradiol by an undisclosed amount. Azur has an option to pay an additional...
BC Week In Review | Jun 29, 2009
Clinical News

Elestrin estradiol regulatory update

BioSante said partner PharmaSwiss S.A. (Zug, Switzerland) submitted an NDA in Israel for Elestrin estradiol to treat moderate to severe hot flashes associated with menopause. PharmaSwiss is responsible for regulatory and marketing activities in Israel...
BC Week In Review | Jan 12, 2009
Company News

Antares, BioSante deal

Antares received a $450,000 milestone payment from BioSante under a 2000 deal that gave BioSante exclusive rights to Elestrin estradiol (formerly Bio-E-Gel ). The payment was triggered by BioSante's December deal with Azur Pharma Ltd....
BC Week In Review | Dec 15, 2008
Company News

Azur Pharma, BioSante sales and marketing update

Azur received exclusive rights to market BioSante's Elestrin transdermal estradiol gel in the U.S. to treat moderate to severe hot flashes associated with menopause. BioSante received $3.3 million up front and is eligible for up...
BC Week In Review | Aug 11, 2008
Company News

BioSante, Nycomed Group A/S sales and marketing update

BioSante reacquired from Nycomed U.S. rights to manufacture, market and distribute Elestrin transdermal estradiol gel to treat moderate to severe hot flashes associated with menopause. Nycomed gained rights to the product in its February acquisition...
BC Week In Review | Dec 24, 2007
Company News

BioSante, Bradley deal

BPA received a $3.5 million milestone from BDY under a deal to market BPA's Elestin to treat moderate to severe hot flashes associated with menopause (see BioCentury, Nov. 13, 2006). This payment was the second...
BC Week In Review | Jun 18, 2007
Company News

BioSante, Bradley sales and marketing update

BDY launched BPA's Elestrin estradiol gel in the U.S. to treat moderate to severe vasomotor symptoms associated with menopause. The price of the bioidentical estradiol transdermal gel is not disclosed. BDY has exclusive U.S. marketing...
BC Extra | May 26, 2007
Financial News

BioSante raises $16.5 million

BPA raised $16.5 million in a private placement of 2.8 million shares at $6. The price is a 12% discount to BPA's close of $6.85 on Thursday. Investors also received warrants to purchase an additional...
Items per page:
1 - 10 of 38